In vivo anti-tumour activity of recombinant human tumour necrosis factor-alpha against Meth-A sarcoma requires L3T4-positive T cells.
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D051379:Mice; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D014409:Tumor Necrosis Factor-alpha